Chondroitin sulfate polyelectrolyte nanoparticles for Controlled Release of Dexamethasone: Improvement of the...

Nanoparticle-based drug delivery systems have revolutionized oncology to overcome some critical burdens of conventional chemotherapy, such as non-specific toxicity, poor drug solubility, and rapid clearance. This study presents chondroitin sulfate (ChS)-based polyelectrolyte nanoparticles to achieve controlled release of dexamethasone (DEXA) while enhancing the anticancer efficacy of curcumin(Cur). The ChS polyelectrolyte nanoparticles (ChSNPs) were synthesized through electrostatic interactions between chitosan (Cs) and Chs polymers. The obtained ChSNPs were used to encapsulate DEXA at different concentrations (i.e. 2.5 %, 5 %, and 10 % w/w). The obtained ChSNPs exhibited spherical nanosize structures with average diameters of 345 ± 78 nm for ChSNPs, 114.83 ± 49 nm for DEXA2.5-ChSNPs, 72.83 ± 12 nm for DEXA5-ChSNPs, and 50.83 ± 12 nm for DEXA10-ChSNPs. The in vitro anticancer potential of Cur against HCT116 was further determined in the presence of DEXA-ChSNPs. the viability cells results reveal that the Cur IC₅₀ was decreased by 3.2-fold when delivered with DEXA5-ChSNPs. The Western blot data reveals a 2.5-fold increase in caspase-3 activity (OD 0.841 vs 0.332 for Cur alone) demonstrates a synthetic lethal interaction between DEXA and Cur in HCT116 cells. These results suggest that DEXA-ChSNPs improve Cur chemosensitivity in colon cancer cells, providing a promising approach for enhanced therapeutic outcomes and reduced side effects in cancer treatment.